Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
27 juin 2023 08h00 HE
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer...
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
20 juin 2023 08h00 HE
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer...
Immutep to Participate at the Jefferies Healthcare Conference
07 juin 2023 08h00 HE
|
Immutep Limited
SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
05 juin 2023 08h00 HE
|
Immutep Limited
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in...
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
02 juin 2023 08h00 HE
|
Immutep Limited
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an...
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
29 mai 2023 08h00 HE
|
Immutep Limited
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to...
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
26 mai 2023 08h00 HE
|
Immutep Limited
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinomaDeep, durable...
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
25 mai 2023 08h00 HE
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
24 mai 2023 08h00 HE
|
Immutep Limited
Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of...
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
17 mai 2023 08h00 HE
|
Immutep Limited
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II...